Securities code: 002432 securities abbreviation: Andon Health Co.Ltd(002432) Announcement No.: 2022-014 Andon Health Co.Ltd(002432)
Announcement on abnormal fluctuation of stock trading and risk warning
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and shall be jointly and severally liable for false records, misleading statements or major omissions in the announcement.
1、 Introduction to abnormal fluctuations in stock trading
Andon Health Co.Ltd(002432) (hereinafter referred to as “the company”) shares (stock abbreviation: IX)
An medical, stock code: 002432) has accumulated more than 20% of the deviation value of the closing price increase for two consecutive trading days (January 13 and January 14, 2022). According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, it belongs to the abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
The company checked the abnormal fluctuation of the company’s share price, and the results are as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage.
2. The company, the controlling shareholder and the actual controller have no major events that should be disclosed but not disclosed or are in the planning stage.
3. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently.
4. The production and operation of the company are normal recently. The company will be on January 13 and January 14, 2022 respectively
Disclosed two major daily operation contract announcements, announcing the contracts signed and orders received by the U.S. subsidiary ihealth labs Inc. with New York and Massachusetts, as well as the purchase contract signed with HHS and ACC, which purchases on its behalf, to provide ihealth kit products to the above counterparties, See the two announcements issued by the company for details. Except for the above matters, the internal and external business environment of the company has not changed significantly.
5. The controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
6. The company does not violate the provisions on fair information disclosure.
3、 Whether there is a description of the situation that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares and their derivatives that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips
From the technical indicators of the secondary market, as of January 14, Hithink Royalflush Information Network Co.Ltd(300033) showed the company’s dynamic P / E ratio of 539.06; In terms of price to book ratio, as of the closing on January 14, the closing price of the company’s shares in the secondary market was 75.28 yuan / share, Hithink Royalflush Information Network Co.Ltd(300033) showed that the company’s price to book ratio was 17.96. At present, the above data of the company are at a high level compared with the company’s historical stock price and P / E ratio, which does not rule out the risk of falling of the company’s stock price and the above indicators in the future.
Please note that the single month performance of the kit product does not represent the annual performance, and the historical performance of the product does not represent the future performance. The company believes that it is necessary to give another risk prompt, as follows:
1. Risk of uncertainty in the development of the epidemic situation in the United States: the demand for the company’s antigen home self-test kit products is directly related to the development of the epidemic situation in the United States. Virus variation, vaccination and the introduction of covid-19 drugs all have an impact on the development of the epidemic situation. Therefore, the development of the epidemic situation in the future has strong uncertainty, This uncertainty may greatly affect the demand of kit products;
2. Uncertainty risk of market competition: at present, a total of 12 companies’ home self-test kit products have been authorized by the U.S. FDA EUA. It can not be ruled out that more companies will obtain such authorization and enter the market to sell kit products in the future. With the change of market competition situation, the existing market share and product price of a single enterprise may be impacted;
3. Rationality risk of valuation model: the sales of the company’s kit products are highly related to the development of the epidemic situation, and the trend of the epidemic situation is difficult to predict, so the long-term impact of the product on the company’s fundamentals is also difficult to predict. Investors should pay attention to the rationality of the stock price combined with their own valuation model, and there are many factors affecting the stock price in the secondary market. Investors should pay attention to investment risk, Rational investment;
4. Reliability risk of information: the company’s answers on the interactive platform are based on the company’s disclosed information, Amazon America’s information and public information. There is no compilation without objective basis, and the information required to be disclosed in the information disclosure regulations of listed companies and not yet disclosed has not been disclosed in any form, especially involving production, sales Sales and other related information. Investors are requested to follow the official information released by the company, do not believe the rumors, and do not presumptuously calculate the sales data and profits of the company’s kit products, resulting in miscalculation and investment loss;
5. Exchange rate fluctuation risk: the company’s kit products are settled in US dollars; With the expansion of sales scale, the amount of foreign currency held by the company will further increase. In view of the uncertainty of exchange rate fluctuations, the company will adjust the product sales price accordingly according to the exchange rate changes, and will consider locking the exchange rate by signing relevant agreements with banks to prevent the risk of large exchange rate fluctuations. However, if the fluctuation range is large in the short term, the company may have exchange losses, which will have an adverse impact on the company’s operating performance;
6. Trade risk to the United States: in terms of trade with the United States, some products of the company are affected by the additional tariff imposed by the United States. Although the proportion of such products is relatively small, if the tariff policy of the United States is further tightened, it may lead to the reduction of the company’s total sales and profits to the United States. In order to cope with the above risks, the company will continue to pay attention to the changes in the international trade situation and adjust its sales and pricing strategies in a timely manner;
7. Logistics and transportation risk: due to the epidemic situation in the United States, the current shortage of transport capacity in air and sea channels continues, port congestion and serious backlog of goods. If the shipped goods cannot be picked up in time, it will have an adverse impact on product sales;
8. Quality risk: in the case of mass production, the batches of individual products may have quality problems, leading to the risk of return or even recall.
9. Order risk: the contract and order execution between the company’s U.S. subsidiaries and New York, Massachusetts and HHS (executed by ACC) are affected by local epidemic changes, policy changes, changes in the company’s supply chain capacity, logistics and transportation risks, unpredictable or force majeure and other factors, There may be a risk that the contract or order cannot be performed on schedule or in full.
It should be noted that the U.S. government has the right to terminate the contract signed between the company’s U.S. subsidiary and U.S. HHS (executed by the U.S. ACC representative) at any time due to its own factors. There is uncertainty about whether the contract can be fully implemented.
In addition, the company also needs to remind investors of the following situations:
1. In the previous announcement, the company mentioned the epidemic prevention related plans issued by the U.S. government, as well as the relevant policies, procurement and distribution plans and conditions of covid-19 antigen household self-test kit products. Investors are reminded that the relevant information and procurement involved in the above contents are not only for the company. Investors are requested not to misunderstand the contents and misinfer the changes it brings to the company’s performance.
2. The sales information disclosed by the company in the previous announcement cannot represent the profit. Because the profit is related to many factors such as raw material cost, product transportation cost, production and manufacturing cost, sales cost, management cost and R & D cost, it is impossible to calculate the profit from the sales amount. Please pay attention to the subsequent announcement of the company for the relevant information of the company’s performance.
3. At present, the company’s share price is at an all-time high, and the risk of falling in the future cannot be ruled out. The company hereby reminds investors that the company will strictly implement the relevant provisions on information disclosure of listed companies and timely fulfill the obligation of information disclosure. It also takes this opportunity to remind investors again that there are many rumors on the Internet platform. Investors are requested to take the information officially released by the company as the standard and do not calculate the company’s performance and future trend without basis. There are many factors affecting the stock price of the secondary market, and the development of the epidemic in the United States in the future is still uncertain. The sales of kit products are affected by many factors. Investors are invited to pay attention to investment risks and invest rationally.
4. The company previously submitted the proposal on using family self-test box to realize Omicron covid-19 epidemic prevention 1 + 1 to Tianjin epidemic prevention and control headquarters. At present, relevant departments are studying the proposal, and it is uncertain whether the proposal will be adopted.
Please correctly interpret the above contents, pay attention to risks and invest rationally.
It is hereby announced
Andon Health Co.Ltd(002432) board of directors
January 15, 2022
